Home New Customer? Create Account
Member Login:

Pathogen Antibodies

151853 - Anti-RSV F Glycoprotein [11-3-A3]


Starting at: $325.00

Please Choose:

Add to Cart:
Cat# 151853
Applications ELISA, IF, Fn, WB
Antigen/Gene or Protein Targets Human Respiratory Syncytial (RS) virus Fusion protein.
Synonyms VGP48, VGP70
Reactivity Virus
Relevance Human Respiratory Syncytial Virus (RSV) is a major cause of lower respiratory tract illness and is the chief cause of hospitalization for respiratory tract illness in young children.The glycoprotein F is located on the surface of viral envelope, its function is to induce fusion of viral envelope with host-cell envelope resulting in syncytium formation. The glycoprotein F (also named VP70, F0 or fusion protein) consists of two components: F1 (also named VPG48) and F2 (also named VGP26) held together by disulphide bonds. The reported molecular weight of the VGP26 component varies between 20 to 26 kd.
Host Mouse
Immunogen Gradient-purified RSF-44 virus (subgroup A) UV inactivated for 20 minutes at 20C
Positive Control Immunoblot: (see Figure) Indirect immunofluorescence: staining of RSA-2 infected BSC-1 cells
Subclass IgG1 kappa
Myeloma Used P3X63Ag8
Recommended Growing Conditions Dulbecco’s media containing 20% Fetal Bovine serum (DH20) prepared as follows (for final volume of 300ml: 237ml DMEM plus 60 ml Fetal Bovine Serum plus 3ml L-Glutamine).
Strain Balb/c
Notes This antibody has a high neutralising activity; 90% plaque neutralization titre of 103 (Gimenez et al., 1996). This property makes it potentially useful for the preparation of reagents for prevention and/or for therapeutic use in managing RS virus infections (for example, vaccines or new–generation man-made antibodies).

This antibody reacts with the fusion protein F (also named VP70 or F0 protein) and specifically to a subunit of the F protein, F1 (also named 48kDa). The antibody reacts with the RS virus F1 protein from both subgroups A and B of the virus.

New-generation man-made antibodies, based on the 11-3-A3 antibody, could complement the effectiveness of polivizumab (Synagis), which is used to prevent but not treat established RS virus infections (Nature Biotechnology, 2013: 31, 952).

Significantly, there was no evidence of antibody dependant enhancement of RS virus infection in vitro for the 11-3-A3 antibody. The enhancing activity was found for other antibodies to the F protein (Gimenez et al 1996).
References Neutralizing and enhancing activities of human respiratory syncytial virus-specific antibodies. Europe PMC ID: 8705669

Antigenic variation between human respiratory syncytial virus isolates. Europe PMC ID: 3517224

Monoclonal antibodies to human respiratory syncytial virus and their use in comparison of different virus isolates. Europe PMC ID: 6202832


Image: The antigen in all lanes was gradient purified RSN-A2 virus (subgroup A). First antibodies: Lanes “MAb”: 11-3-A3 antibody; Lanes “HuS”: RS virus convalescent human sera. Panel A: Antigen analysed by electrophoresis using reducing conditions (SDS and mercapthoethanol). Panel B: Antigen analysed by electrophoresis using non reducing conditions (SDS only) (Gimenez et al., 1986). The identity and molecular weight of the protein target of this antibody was validated by including within the immunoblot assay (as a marker) a convalescent serum sample from a RSV infected patient. The protein specificities of the antibodies induced in the human convalescent serum is described in Gimenez et al. (1987).


For Research Use Only.